Elenagen is under clinical development by CureLab Oncology and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase II drugs for Kidney Cancer (Renal Cell Cancer) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elenagen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Elenagen is under development for the treatment of triple negative breast cancer, ovarian cancer, lung cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, renal cancer, Inoperable stomach cancer (gastric cancer), glioblastoma, metastatic uterine cancer, pancreatic cancer, melanoma, age related macular degeneration and neurodegenerative diseases. The drug candidate is a DNA vaccine encoding p62/SQSTM1 plasmid. It is administered by intramuscular route. It was also under development for appetite disorder.
CureLab Oncology overview
CureLab Oncology (CureLab) is a biotechnology company that develops anti-cancer biologics and clinical trails. The company is headquartered in Boston, Massachusetts, the US.
For a complete picture of Elenagen’s drug-specific PTSR and LoA scores, buy the report here.